WAYNE, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an expansion to the Indications for Use of the QuikClot Control+™ Hemostatic Device to include all grades of internal and external bleeding. The QuikClot Control+™ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical w ...

WAYNE, Pa., April 24, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the presentation of several clinical studies at the 2025 American Urological Association Annual Meeting, which is being held in Las Vegas from April 26 - 29, 2025. These studies contribute to the expanding body of clinical and real-world evidence supporting innovations in benign prostatic hyperplasia (BPH) treatment and rectal spacing to protect tissue during ra ...

WAYNE, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 1, 2025. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning ...

WAYNE, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced FDA 510(k) clearance of the AC3 Range™ Intra-Aortic Balloon Pump (IABP). Leveraging the patented technology of the AC3 Optimus™ IABP, the AC3 Range™ IABP is designed to provide reliable, ongoing IABP support across various patient transport modes, including ambulances and both fixed- and rotary-wing aircrafts. The AC3 Range™ IABP combines the simple interface an ...

Prospective Multicenter Study Investigates Ringer™ PBC for Management of Coronary PerforationsWAYNE, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the preliminary results from its Ringer™ PBC IDE study were reported in a featured presentation at the CTO Plus Conference in New York by the study’s principal investigator, David E. Kandzari, MD, FACC, MSCAI, Chief, Piedmont Heart Institute and Cardiovascular Ser ...

WAYNE, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that new findings from the CLEAR study were presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, which took place March 21-24, 2025. Among the results, the study showed better early patient satisfaction and sexual function with the UroLift™ System (PUL) compared to Rezūm™ Water Vapor Therapy (WVTT).1 CLEAR is the first head-to-h ...

Core Insights - Teleflex is undergoing a significant strategic transformation by planning to separate into two independent publicly traded companies to enhance shareholder value [2][3] - The company is also acquiring Biotronik's Vascular Intervention business for approximately EUR 760 million, which will strengthen its interventional portfolio [4][5] - Despite facing near-term growth challenges, management remains confident in the long-term benefits of the separation and acquisition strategy [6][7] Strategic Corporate Split - The separation is expected to be completed by mid-2026, allowing each new entity to focus on distinct markets and growth opportunities [2][3] - The "RemainCo" business will encompass Vascular Access, Interventional, and Surgical businesses, projected to achieve over 6% revenue growth post-separation [7] Acquisition Details - The acquisition of Biotronik's Vascular Intervention business aims to enhance Teleflex's presence in catheterization labs and access to expanding markets [4][5] - The deal is anticipated to close by the end of the third quarter of 2025, significantly expanding Teleflex's market presence in the coronary and peripheral interventional sectors [5] Financial Outlook and Challenges - The company faces headwinds limiting near-term growth, including challenges in the UroLift business, OEM inventory management issues, and volume-based procurement impacts in China, totaling approximately $100 million in expected losses [5][6] - Management has set a revenue growth guidance of 1% to 2% for the upcoming year, reflecting the current trading environment [6] Management's Strategic Vision - The separation into two focused companies is designed to accelerate growth with a simplified operating model and increased management focus [8] - The company aims to position itself for stronger future performance through strategic acquisitions and operational focus despite current market challenges [6][7]

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Teleflex Incorporated (NYSE: TFX) for potential violations of the federal securities laws. If you invested in Teleflex, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/teleflex-incorporated. Why is Teleflex being Investigated? Teleflex is a global provider of medical technology products used by hospitals and healthcar ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Teleflex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 27, 2025 ...

Core Viewpoint - Teleflex management is attempting to change the course of the business after years of mediocre performance by announcing a significant acquisition and a plan to split the business into "Teleflex Classic" moving forward [1] Group 1 - Teleflex has experienced years of mediocre performance prior to the recent management changes [1] - The company is pursuing a significant acquisition as part of its strategy to improve performance [1] - A business split is planned, with the establishment of "Teleflex Classic" as a new direction for the company [1]